Loading data for SCNX — first visit, this takes a few seconds.
Scienture Inc. (SCNX)
NasdaqCM: SCNX
· Real-Time Price · USD
0.39
+0.01 (2.63%)
At close: Aug 28, 2026, 3:59 PM
0.39
-0.94%
After-hours: 7:29 PM
The price, the headline numbers and the latest news, in one place.
Scienture Inc. (SCNX) Stock Price, Analysis & Data
2.63% (1D)
| Bid | 0.03 |
| Market Cap | 16.18M |
| Revenue (ttm) | 821.32K |
| Net Income (ttm) | -37.95M |
| 3.96 | |
| -2.03 | |
| n/a | |
| n/a | |
| P/B (ttm) | 0.25 |
| P/S (ttm) | 19.70 |
| Earnings Date | n/a |
| Ask | 0.4 |
| Volume | 270,264 |
| Avg. Volume (20D) | 2,554,641 |
| Open | 0.40 |
| Previous Close | 0.38 |
| Day's Range | 0.38 - 0.40 |
| 52-Week Range | 0.24 - 2.60 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | Jul 19, 2024 |
About SCNX
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left vent...
Industry Pharmaceutical Retailers
Sector Healthcare
IPO Date Feb 6, 2014
Employees 4
Stock Exchange NasdaqCM
Ticker Symbol SCNX
Website https://scienture.com
Financial Performance
In 2025, Scienture's revenue was 431.61K, an increase of 215.87% compared to the previous year's 136.64K. Earnings were -41.51M, a decrease of -557.9%.
Financial StatementsEarnings Surprise
Scienture has released their quarterly earnings on Aug 13, 2026:
- Revenue of $56.33K misses estimates by $0, with 449.08% YoY growth.
- EPS of -0.07 exceeds estimates by 0.02, with -Infinity% YoY decline.
5 months ago · Associated Press Finance
BC-Most Active StocksElong Power Holding Ltd. 79,546,080 0.0559
Page 1 of 2